Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety, ADHD, non-neurological conditions of cancer, and non-alcoholic steatohepatitis. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.